EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Jair Bar*, Arnold Cyjon, Dov Flex, Hadas Sorotsky, Haim Biran, Julia Dudnik, Nili Peylan-Ramu, Nir Peled, Hovav Nechushtan, Maya Gips, Rivka Katsnelson, Shoshana Keren Rosenberg, Ofer Merimsky, Amir Onn, Maya Gottfried

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients. Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients. Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy. Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.

Original languageEnglish
Pages (from-to)759-763
Number of pages5
Issue number5
StatePublished - 1 Oct 2014


  • Biopsy site
  • Common practice
  • EGFR testing
  • Non-squamous


Dive into the research topics of 'EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this